ASH Annual Meeting and Exposition
ASH Annual Meeting and Exposition
January 11, 2016
2 min watch
Save

VIDEO: Addition of elotuzumab to lenalidomide, dexamethasone safe, effective for myeloma

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

ORLANDO, Fla. — Paul G. Richardson, MD, offers insights into results of a study presented at the ASH Annual Meeting and Exposition that showed the addition of elotuzumab to lenalidomide and dexamethasone conferred sustained PFS benefits for patients with multiple myeloma.